BS_JBGZ7HHZ
ganglioneuroblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- ganglioneuroblastoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- ganglioneuroblastoma
- overall_survival_months
- 41.49145860709592
- age_years
- 4.567
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.635
- ALLOGRAFT_REJECTION+0.613
- INTERFERON_GAMMA_RESPONSE+0.606
- INFLAMMATORY_RESPONSE+0.515
- IL6_JAK_STAT3_SIGNALING+0.512
- ANGIOGENESIS+0.472
- COAGULATION+0.466
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.438
- COMPLEMENT+0.427
- APICAL_SURFACE+0.414
Top 10 suppressed
- MYC_TARGETS_V2-0.423
- MTORC1_SIGNALING-0.410
- OXIDATIVE_PHOSPHORYLATION-0.383
- CHOLESTEROL_HOMEOSTASIS-0.366
- MYC_TARGETS_V1-0.357
- UNFOLDED_PROTEIN_RESPONSE-0.295
- PROTEIN_SECRETION-0.285
- ADIPOGENESIS-0.246
- E2F_TARGETS-0.233
- GLYCOLYSIS-0.230
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR821602 | GTEX | — | 0.926 |
| 2 | e5b29c06-2ed0-4913-bf24-5bfde047defc | — | — | 0.925 |
| 3 | MNG303 | — | — | 0.912 |
| 4 | TCGA-55-6979-01A-11R-1949-07 | — | cohortA1 | 0.909 |
| 5 | BS_FRM9TG02 | Neurofibroma | — | 0.905 |
| 6 | TCGA-MP-A4TI-01A-21R-A24X-07 | — | cohortA1 | 0.904 |
| 7 | SRR599510 | GTEX | — | 0.900 |
| 8 | TCGA-55-8299-01A-11R-2287-07 | — | cohortMD2 | 0.900 |
| 9 | MDT-AP-0363 | Med | Medulloblastoma | 0.898 |
| 10 | MDT-AP-1177 | Med | Medulloblastoma | 0.896 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.635 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.613 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.606 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.515 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.512 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.472 | Remibrutinib | — uncovered |
| COAGULATION | 0.466 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.438 | Inavolisib | — uncovered |
| COMPLEMENT | 0.427 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.414 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.395 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.376 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.331 | Idelalisib | — uncovered |
| APOPTOSIS | 0.295 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.208 | Inavolisib | — uncovered |
| MYOGENESIS | 0.148 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.138 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.098 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.087 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.087 | Inavolisib | — uncovered |